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Background: Adherence to antiretroviral therapy is a necessity for the attainment of favorable treatment outcomes.  
Several factors are known to influence adherence levels among different cohorts of patients. These factors are likely to 
be different for patients on second line therapies and knowing them might improve the quality of care provided and 
generally raise adherence levels.  
Objective: To determine adherence levels and their determinants in people living with HIV on second line therapy. 
Methods: A cross-sectional study was undertaken in a HIV clinic within Kenyatta National Hospital in October, 2017. 
Data were collected through interviews and adherence was assessed by oral interview of past medication use and 
then analyzed in R. 
Results: One hundred and ten patients were enrolled; 46 (41.8%) of whom were males. The mean age was 39.8 years 
(± 11.8). Most participants, 96 (87.3%), were moderately adherent while 14 (12.7%) had low adherence. None were 
highly adherent. Age (aOR = 1.10, 95% CI; 1.04, 1.19) and depression (aOR =0.17, 95% CI 0.04, 0.64) were 
independently associated with adherence.  
Conclusion: None of the patients on second line regimens were highly adherent to therapy. Younger patients and 
those with depression require additional adherence counselling.   
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1. Introduction 
Adherence is defined as “the extent to which a person’s 
behavior – taking medication, following a diet, and/or 
executing lifestyle changes, corresponds with agreed 
recommendations from a health care provider” (World 
Health Organization, 2003). Adherence to antiretroviral 
therapy (ART) is an important and overriding 
component towards the achievement of optimal 
treatment outcomes for people living with HIV (PLHIV) 
on follow up. Adherence levels above 95%, otherwise 
referred to as high adherence, have been associated 
with better outcomes such as viral suppression, slowing 
of disease progression, decreased morbidity and 
mortality among others (Conway, 2007). Moreover, 
high initial adherence is reported to be crucial in 
determining long term optimal virological and 
immunological outcomes. High adherence initially and 
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medium adherence in the maintenance phase are 
demonstrated to result in much favorable values of CD4 
count and viral load (Maria Patrizia Carrieri et al, 2003).  
Maintaining high adherence levels is challenging. 
Reports from both high, low and middle countries in 
North America and sub Saharan Africa (sSA) indicate 
that the ≥ 95% adherence threshold is not usually 
attained with pooled estimates of 55% and 77% 
respectively for the aforementioned continents (Mills et 
al, 2006). Though in this meta-analysis, patients in 
countries in sSA were found to have higher adherence 
levels than the North American countries, it is of 
concern that adherence levels have been declining over 
time (Byakika-Tusiime et al, 2009; Liu et al, 2006; 
Parruti et al, 2006). This decline and the changes in 
adherence over time are not unique to these regions 
and have also been reported in a French cohort (P. 
Carrieri et al, 2001).  
Failure to adhere to ART has been correlated with 
changing circumstances over time (M. P. Carrieri et al, 
2003). Some of the factors associated with adherence 
levels lower than 50% (defined as poor adherence) in 
sSA are patient characteristics such as depression 
(Mayston et al, 2012; World Health Organization, 2003), 
poor service provision (Watt et al, 2010) and structural 
factors like distance to the health facility (Lankowski et 
al, 2014). These risk factors for adherence differ 
between regions and are context specific (Ware et al, 
2009). Understanding them will enable healthcare 
workers to provide tailored care for those at risk of 
non-adherence. Patients on second line ART may have 
been on these regimens for a number of reasons such as 
virological, immunological or clinical failure. These 
regimens tend to have a higher pill burden, require an 
increased dosing frequency and have more severe side 
effects (Moosa et al, 2019). These reasons, among 
others yet to be identified in our context, could 
contribute to low adherence in this group of patients. 
Poor adherence in this subset of patients could have 
adverse effects beyond the individual and impacting on 
the public HIV healthcare system. For instance, the costs 
of hospitalization are reported to rise from 29% to 51% 
due to decreased adherence (Nachega et al, 2010). 
Compounded with risky sexual behavior, transmission 
of resistant strains to ART naïve patients would worsen 
the problem (Cambiano et al, 2013).   
Owing to the paucity of local data on adherence levels 
among PLHIV on second line ART regimens and the 
associated factors, we designed a cross sectional study 
with the aim of filling the gap. In addition, risk factors 
for poor adherence were evaluated. 
2. Methods 
2.1 Study design and site  
A cross sectional study was conducted at the 
Comprehensive Care Clinic (CCC) of Kenyatta National 
Hospital (KNH), Nairobi, Kenya.  
2.2 Study population and eligibility criteria  
Patients were eligible if they had a documented HIV 
infection, were 18 years or older, were enrolled for care 
at the clinic, voluntarily provided written informed 
consent and had been on an atazanavir/ritonavir based 
second line regimen for more than one month. They 
were excluded if they were pregnant or lactating 
(vulnerability and ethical concerns), had a World Health 
Organization (WHO) stage IV illness (concomitant 
interacting medications, frailty), had a documented 
creatinine clearance of less than 60 mL/min (alteration 
to pharmacokinetic parameters), had ever experienced 
hyperbilirubinemia (confounding variable) or were on 
certain co-medications (proton pump inhibitors, 
histamine 2 receptor antagonists or rifampicin).  
2.3 Sampling and enrollment 
Patients on second line ART regimens consisting of 
atazanavir were identified from the records department 
and their upcoming clinic dates noted. A random 
number generator was used to identify the patients that 
would be recruited. They were then called by the 
counsellor as part of routine follow up and requested to 
avail themselves to the counsellor’s office regarding 
possible study participation. Upon reporting, the 
patients were briefed about the study, taken through 
screening using an eligibility checklist and those who 
met the eligibility criteria were enrolled consecutively. 
Informed consent was obtained before enrollment. 
The calculated sample size was 109 using the Kelsey et 
al. (1996) (Kelsey, 1996) formula for sample size 
estimation. We enrolled an additional 10 % to cater for 
non-completeness of data.  
2.4 Data collection 
Trained research staff, who were clinicians within the 
clinic, administered pre-designed standardized case 
report forms and carried out chart reviews while 
collecting demographic and clinical history data. 
Adherence was assessed by asking patients whether 
they sometimes forgot to take their medication. This 
question required a simple ‘yes’ or ‘no’ response.  
Patients were asked additional questions to identify 
reasons for non-compliance.  They were also asked 
whether they reported non-adherence to the clinician. 
2.5 Data analysis 
Hard copy data was transferred to a database that was 
created in Epi Info (version 7, CDC, Atlanta, GA, USA). 
Statistical analysis was done on the resultant data set in 
R (version 3.5.2 (2018-12-20)). Categorical variables 
were summarized in frequency tables and continuous 
measures were summarized using means and standard 
deviations or medians and ranges, as appropriate. The 
Shapiro Wilk test and Q - Q plots were used to test for 
normality of the data, whereas the student t-test was 
used to check for differences in means of continuous 
variables and the Chi-square test for discrete variables. 
In the covariate search, logistic regression modelling 
was performed using backward stepwise selection to 
identify variables to fit the model. The threshold for 
statistical significance was set at 0.05.  
2.6 Ethical considerations 
All procedures performed in this study involving human 
participants were in accordance with the ethical 
standards of the Kenyatta National Hospital and 
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University of Nairobi Ethics and Research Review 
Committee (Approval reference: KNH-ERC/A/110) and 
with the 1964 Helsinki declaration and its later 
amendments or comparable ethical standards. 
Participants provided written informed consent prior to 
taking part in this study. 
3. Results  
A total of 236 patients were screened between October 
and November 2017 with the subsequent enrollment of 
110 individuals, majority of whom were women (64, 
58.2%; Table 1). The mean age of the study population 
was 39.8 (± 11.8) years. Approximately half the 
participants were married (59, 53.6%) and had attained 
secondary school education (56, 50.9%). Nearly a third 
were unemployed (30, 27.3%) and less than 10% had 
hypertension or diabetes (9.1% and 4.5%, respectively). 
The median CD4 count was 219 cells/mL (IQR = 272) 
and half the participants had achieved viral 
suppression.   
 
Table 1: Baseline characteristics of the study population 
Variables n % 
Sex  
Male  
Female  
 
46 
64 
 
41.8 
58.2 
Age in years; mean (SD) 39.8 (11.8)  
Marital status: n (%)  
Single  
Married  
Separated 
Divorced  
Widowed  
 
34 
59 
10 
1 
6 
 
30.9 
53.6 
9.1 
0.4 
5.5 
Number of children; median (Range) 2 (0-3)  
Level of education 
Primary  
Secondary  
Tertiary  
Informal education   
 
24 
56 
29 
1 
 
21.8 
50.9 
26.4 
0.9 
Occupation; n (%)  
Unemployed  
Self employed 
In formal employment   
Smoke cigarettes; n (%) 
Alcohol consumption; n (%)  
 
30 
43 
37 
2 
12 
 
27.3 
39.2 
33.6 
1.8 
10.9 
Hypertension; n (%) 
Diabetic; n (%) 
CD4 count; median (IQR) 
Viral load; n (%) 
< 1000 copies/mL 
Time since diagnosis of HIV; median (IQR) years 
Duration on antiretroviral therapy; mean (SD) years 
Regimen ever modified; n (%) 
Reason for regimen modification; n (%)  
Regimen failure  
Toxicity  
Other  
Current opportunistic infections; n (%) 
10 
5 
219 (272) 
 
55 
9.4 (3.8) 
8.4 (3.3) 
108 
 
105 
3 
2 
10 
9.1 
4.5 
 
 
50 
 
 
98.2 
 
95.5 
2.7 
1.8 
9.1 
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Table 2: Participant responses to questions on adherence 
 Item description No (n, %) Yes (n, %) 
1 Do you on occasions forget to take your medicines?  
 
90 (81.8) 20 (18.2) 
2 In the last 14 days, were there any days when you did not take your medicines 
for reasons other than forgetting?   
105 (95) 5 (4.5) 
 Reasons for non-adherence    
3 Have you ever reduced the frequency/ quantity or stopped taking your 
medicine without telling your doctor because you felt worse when you took it?  
 
104 (94.5) 6 (5.5) 
4 Do you sometimes forget to carry your medicine when you travel?  
 
101 (91.8) 9 (8.2) 
6 Do you sometimes stop taking your medicine when your symptoms have gone 
away?     
                                          
106 (96.4) 4 (3.6) 
7 Have you felt inconvenienced by strictly following your treatment plan?       
  
94 (85.5) 16 (14.5) 
8 How often do you have difficulty remembering to take all your medicine?  
 
  
 Never 
(n (%)) 
 
1 (0.9) 
Once in a while 
(n (%)) 
 
8 (7.3) 
Sometimes 
(n (%)) 
 
25 (22.7) 
Usually 
(n (%)) 
 
76 (69.1) 
All the time 
(n (%)) 
 
0 
  
 
Fourteen (12.7%) of the participants had low adherence 
while 96 (87.3%) were moderately adherent to ART. 
None of the participants had high adherence. The 
reasons for non-adherence are listed in Table 2.    
The most common reason for non-adherence to ART 
was forgetting to take the medications (20, 18.2%) 
(Table 2). A considerable number of patients also felt 
that their treatment plans were an inconvenience and 
this resulted in non-adherence as well (16, 14.5%). 
Interestingly, all participants reported that they had 
taken their dose the day prior to their clinic visit. 
On bivariable logistic regression analysis, age, marital 
status and occupation were found to be significantly 
associated with adherence level (Table 3). In this case, 
a one-year increase in age was associated with 6% 
higher adherence levels among the participants (cOR 
1.06, 95% CI (1.01, 1.12), p =0.023). Married 
participants had 3.89 higher odds of being moderately 
adherent in comparison to those who were single (cOR 
3.89, 95% (CI 1.22, 13.79), p=0.026). Self-employed 
participants had 8.79 times higher odds of being 
moderately adherent to ART compared to unemployed 
individuals (cOR 8.79, 95% CI (2.04, 61.17), p=0.09). 
Similarly, participants who were formally employed had 
4.86 times higher odds of being adherent to ART 
compared to the unemployed (cOR 4.86, 95% (1.29, 
23.80), p= 0.029).  
On logistic regression analysis with backward stepwise 
model building, age and depression were found to be 
significantly associated with adherence (Table 3).  
Participants older by one year were more likely to have 
a 10% higher adherence compared to younger 
participants holding all other variables constant (aOR 
1.10, 95% CI (1.04, 1.19), p =0.004). A positive 
depression screen was associated with an 83% lower 
likelihood of adhering to ART compared to participants 
with a negative screen holding all other variables 
constant (aOR 0.17, 95% CI (0.04, 0.64), p =0.013).  
4.0 Discussion 
In this cross-sectional study involving PLHIV on second 
line regimens, none of the participants were highly 
adherent to treatment. Most had moderate adherence 
(96, 87.3%) while a smaller number had low adherence 
(14, 12.7%). Age and possible depression were 
identified as being independently associated with 
adherence status.  
In a French cohort of PLHIV who were also intravenous 
drug abusers (IVDU), 22.9% of the participants had low 
adherence which is much higher compared to our 
findings (M. P. Carrieri et al, 2003). Adherence was 
determined by self-report which is subjective, but 
nonetheless, the high non-adherence rate was also 
understandable since substance abuse has been 
identified as a determinant in a meta-analysis 
(Langebeek et al, 2014).  
Across Asia, the levels of adherence vary greatly, not 
unexpectedly, as it has been noted that the facilitators 
and barriers of adherence are context specific. The rates 
of adherence in China and Indonesia are 72% and 54% 
respectively, both of which are lower than what we 
report (Kipsang et al, 2018; Rai et al, 2013). However, in 
Myanmar, the documented adherence level is congruent 
to ours at 84% (Aye et al, 2017). Differences in the tools 
used to assess adherence may also explain the variances 
in part. 
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Table 3: Bivariable and multivariable logistic regression analysis for association between demographics, clinical 
characteristics and adherence levels in patients on second line regimens 
Variables  cOR (95% CI)  P value aOR (95% CI) P value 
Age   1.06 (1.01, 1.12) 0.023 1.10 (1.04, 1.19) 0.004 
Gender  1.46 (0.47, 4.59) 0.508 - - 
Marital status  
Single  
Married  
Separated, Divorced,  
Widowed 
 
1 
3.89 (1.22, 13.79) 
- 
 
 
 
0.026 
0.992 
 
- - 
Education  
Primary  
Secondary  
Tertiary  
 
1 
0.22 (0.01, 1.26) 
0.26 (0.01, 1.92) 
 
 
0.159 
0.244 
- - 
Occupation  
Unemployed  
Employed 
 
1 
6.43 (2.01, 22.91) 
 
 
0.002 
- - 
Alcohol use  0.38 (0.10, 1.90) 0.19 0.18 (0.03, 1.21) 0.069 
Hypertension  0.55 (0.12, 3.89) 0.475 0.12 (0.01, 1.39) 0.080 
Diabetes  0.57 (0.08, 11.51) 0.622 - - 
Depression  0.32 (0.09, 1.00) 0.055 0.17 (0.04, 0.64) 0.013 
Regimen modification - 0.993 - - 
Current opportunistic infection 0.29 (0.07, 1.48) 0.102 - - 
Years on ART  0.87 (0.72, 1.03) 0.124 0.84 (0.67, 1.03) 0.106 
cOR – crude odds ratio; aOR – adjusted odds ratio 
Regionally, adherence levels to ART are comparable to 
our findings. In Botswana and South Africa, the 
documented adherence levels are approximately 87% 
(Ehlers & Tshisuyi, 2015; Mabunda et al, 2019), though 
this was ascertained through pill counts. In West Africa, 
adherence levels to ART range between 78 – 90%; these 
were determined by pill counts and self-report 
(Potchoo et al, 2010; Yaya et al, 2014). In East Africa, 
specifically Tanzania, Uganda and Ethiopia, adherence 
levels between 52 and 95% have been reported, 
measured by a number of methods including the visual 
analogue scale, pharmacy refills, appointment keeping 
and pills consumed in a week (Letta et al, 2015; Sangeda 
et al, 2018; Watt et al, 2010). A prospective study 
conducted in Kenya at the African Medical Research 
Foundation (AMREF) clinic in Kibera reported that 
close to 38% of the patients were non adherent (Unge et 
al, 2010). This is about three times of what we report as 
poor adherence, yet these two clinics and patients are 
drawn from the Nairobi metropolitan area. The 
differences could be attributed to the fact that Kibera is 
an area mostly inhabited by individuals of low social 
economic status and as such issues such as stigma and 
food scarcity compete for attention with adherence to 
ART.  
Older individuals are more likely to be stable – socially 
and economically, mature and with more 
responsibilities and may therefore take their treatment 
more seriously than young individuals (Watt et al, 
2010). We also identified probable depression as being 
significantly associated with adherence, which has also 
been reported across multiple studies in diverse 
settings (M. P. Carrieri et al, 2003; Langebeek et al, 
2014; Letta et al, 2015; Protopopescu et al, 2009). 
Depression, where definitively diagnosed, is a known 
risk factor for non-adherence based on the premise that 
persons with mental illness are less likely to find 
motivation in keeping with the prescribed treatment 
regimens.  
Alcohol use has previously been reported as a 
determinant of non-adherence (Bukenya et al, 2019; 
Denison et al, 2015; Protopopescu et al, 2009; Sangeda 
et al, 2018; Yaya et al, 2014), though this was not 
identified in this study. Persons who use alcohol 
excessively are less likely to remember to take their 
medication on time or even to take them at all. Though 
not a risk factor in this population, duration on ART has 
been identified as a determinant for adherence in South 
African and Chinese cohorts (Kipsang et al, 2018; Moosa 
et al, 2019). We hypothesize that patients who have 
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been on ART longer are more likely aware of its benefits 
and become more adherent.  
Nine percent of the study population had hypertension 
as a comorbidity, which was not unexpected as protease 
inhibitors are associated with an increased risk of 
metabolic syndrome (Barbaro, 2006). PLHIVs on ART 
can expect a near normal population life expectancy, but 
due to the metabolic syndrome, conditions such as 
hypertension and diabetes are highly prevalent. In an 
urban population of PLHIV on therapy,  31.7% were 
found to have hypertension, which was much higher 
than what we found (Monroe et al, 2013). Many  
comorbidities are known to impede adherence, 
primarily due to the pill burden (Krentz et al, 2012), but 
also due to competing interests and a lack of 
understanding of the conditions (Monroe et al, 2013). 
Forgetfulness  is documented to be the most common 
cause of non-adherence, a finding that we replicated 
(Croome et al, 2017; Kipsang et al, 2018; Letta et al, 
2015; Semvua et al, 2017). To decrease the contribution 
of this factor, use of innovative methods such as setting 
alarms to remind patients to take their medications 
might work. Other documented reasons for non-
adherence include side effects associated with ART and 
travelling. 
Our study provides insights to healthcare providers on 
how best to improve adherence among PLHIV by being 
more attentive to the young and those likely to be 
depressed. The cross-sectional nature of the study 
design did not allow us to investigate causality or to 
determine the dynamic nature of adherence with time. 
There are also variables such as disclosure and 
adherence self-efficacy that were not investigated upon 
and could potentially influence adherence to ART. Data 
on these variables and others could be collected in 
future studies that may be longitudinal in nature. 
Optimum adherence to ART is key in ensuring 
treatment success and reducing adverse outcomes such 
as increased mortality (Rai et al, 2013). Treatment 
programs should ensure that measures such as frequent 
counselling (Ehlers & Tshisuyi, 2015), having family 
support (Letta et al, 2015), encouraging patients to have 
adherence partners (Ehlers & Tshisuyi, 2015) as well as 
diagnosis and treatment of mental illness are prioritized 
to enhance adherence. 
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